Kennedy Capital Management LLC Has $1.58 Million Position in BioNTech SE (NASDAQ:BNTX)

Kennedy Capital Management LLC increased its holdings in shares of BioNTech SE (NASDAQ:BNTX) by 258.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 13,820 shares of the company’s stock after purchasing an additional 9,964 shares during the period. Kennedy Capital Management LLC’s holdings in BioNTech were worth $1,575,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. State Street Corp increased its stake in shares of BioNTech by 2.0% during the third quarter. State Street Corp now owns 155,867 shares of the company’s stock worth $18,512,000 after purchasing an additional 3,014 shares during the period. Exome Asset Management LLC bought a new position in BioNTech during the 3rd quarter worth $4,104,000. GAMMA Investing LLC lifted its holdings in shares of BioNTech by 48.2% during the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock worth $105,000 after buying an additional 300 shares in the last quarter. Retireful LLC bought a new stake in shares of BioNTech in the fourth quarter valued at about $260,000. Finally, Atomi Financial Group Inc. grew its stake in shares of BioNTech by 6.7% in the fourth quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company’s stock valued at $414,000 after acquiring an additional 229 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Citigroup initiated coverage on shares of BioNTech in a report on Thursday, March 13th. They issued a “buy” rating and a $145.00 price objective for the company. Truist Financial started coverage on BioNTech in a research report on Friday, January 10th. They set a “buy” rating and a $172.00 price target on the stock. Morgan Stanley dropped their price objective on BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. BMO Capital Markets increased their target price on BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.44 price target on shares of BioNTech in a research note on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and a consensus price target of $143.44.

BioNTech Stock Performance

NASDAQ BNTX opened at $102.34 on Tuesday. The firm’s fifty day moving average price is $104.24 and its two-hundred day moving average price is $111.51. The stock has a market cap of $24.56 billion, a PE ratio of -48.73 and a beta of 1.07. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.90 EPS. On average, equities analysts expect that BioNTech SE will post -3.88 EPS for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.